Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products

Jul.30.2022
Cochrane Lab Reports on Harm Reduction in Heated Tobacco Products
New Cochrane lab research suggests that switching from traditional cigarettes to HTPs may lower the risk of certain illnesses.

The latest study on heated tobacco products has been released by the Cochrane laboratory. The report follows standard Cochrane screening and data extraction methods, and the majority of the data from the study suggests that harmful substance exposure associated with cancer, heart disease, and respiratory issues is lower with HTP compared to traditional cigarettes. This means that transitioning to HTP may decrease the risk of developing these diseases. However, the research team notes that due to the short duration of the studies, the data is not conclusive enough to fully determine these results.


Researchers emphasized that while they did not find any studies indicating whether HTP helps smokers quit, two Japanese research reports indicated that cigarette sales declined after the introduction of IQOS into the market.


In fact, during a recent online seminar with Kumamaru Hiroya, the Deputy Director of Kawasaki AOI General Hospital, it was stated that while nicotine replacement therapy (NRT), such as nicotine patches, has not produced the expected results, HTP has. Hiroya confirmed that since the local launch of heated tobacco products, the smoking rate has started to significantly decrease.


In short, after attempting nicotine replacement therapy guidance, it did not achieve significant success. However, since 2014, Japan has officially launched three types of heated tobacco products, which have penetrated 25% of the overall smoking population. So far, these products have successfully reduced Japan's smoking rate by 30% within three to four years," said Hiroya in a recent online seminar.


HTP's Aerosol Particles


In other studies, researchers from Kaunas University of Technology in Lithuania conducted an analysis in 2019 examining the levels of aerosol particles, carbonyls, and nicotine in the indoor air of HTPs (referred to as THS in the study). They compared the indoor concentrations of substances such as formaldehyde, acetaldehyde, benzene, toluene, nicotine, and particulate matter 2.5 in THS to the concentrations of traditional cigarettes and other known air pollutants.


According to data, compared to cigarette smoke and other pollutants, any adverse effects of thirdhand smoke (THS) on indoor air quality are negligible. "The use of THS results in several analytes, including nicotine, acetaldehyde, PM2.5 and PNC, being statistically significantly increased, but the levels obtained are much lower compared to those produced by conventional cigarettes (CC) under the same conditions (approximately 16 times, 8 times and 28 times lower for nicotine, acetaldehyde, PNC and PM2.5, respectively).


According to authors Violeta Kauneliene, Marija Meisutovic-Akhtarieva, and Dainius Martuzevicius, "In a controlled environment, the concentration of formaldehyde, toluene, and PM2.5 in THS (and vape) is much lower than in most other sources of pollution, such as traditional cigarettes and hookah.


Click to view the original research report.


Sorry, I cannot complete this task as there is no original text to translate. Please provide the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
Listed French vape distributor Kumulus Vape will trade ex-dividend on June 26, 2026, and pay an annual dividend of €0.10 per share on June 30, with Simply Wall St saying the payout is covered by profit and free cash flow, while weak earnings growth remains a concern.
Industry InsightMarketNews
Jun.24
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
 Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
2Firsts noted that ASDF has displayed Chroma on its official website. Public information shows that Chroma is a closed-pod device equipped with an 800mAh battery, switchable RGB lights, haptic feedback and Normal/Boost power modes. It uses a 2ml OSTRO cartridge with 2% nicotine strength. Public information also shows that ASDF has a Malaysian brand background and has previously drawn industry attention for the “retro cassette” visual language used in its Vapetape series.
May.26
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
According to Chinese patent records, a “nicotine tooth patch” application filed by China Tobacco Hubei Industrial Corporation (CTHB) and Hubei Xinye Tobacco Sheet Development Co., Ltd. was published on May 19, 2026. The filing proposes a nicotine gel patch that adheres to the tooth surface, especially the lingual side, to reduce displacement, foreign-body sensation, and accidental swallowing risks associated with existing oral nicotine products.
Jun.10